



## Novel Therapeutic Strategies for Glioblastoma

Guest Editors:

**Dr. Milica Pešić**

Department of Neurobiology,  
Institute for Biological Research  
"Siniša Stanković" - National  
Institute of Republic of Serbia,  
University of Belgrade, Belgrade,  
Serbia

**Dr. Ana Podolski-Renić**

Department of Neurobiology,  
Institute for Biological Research  
"Siniša Stanković" - National  
Institute of the Republic of  
Serbia, University of Belgrade,  
Belgrade, Serbia

**Dr. Jelena Dinić**

Department of Neurobiology,  
Institute for Biological Research  
"Siniša Stanković" - National  
Institute of the Republic of  
Serbia, University of Belgrade,  
Belgrade, Serbia

### Message from the Guest Editors

Dear Colleagues,

Adult glioblastoma is the most common and most aggressive type of primary brain cancer. It is a highly heterogenic cancer whose malignant cells are invasive and intrinsically resistant to any applied therapy. Despite numerous clinical studies that have been conducted in the last two decades, glioblastoma remains unresponsive to diverse available therapies (targeted molecular therapeutics, cellular and immune therapies, as well as alternating electrical fields). The standard procedure, dating from 2005, is surgical resection followed by radiotherapy with concomitant temozolomide chemotherapy; it has failed to prolong glioblastoma patient survival. Therefore, new therapeutic strategies that can overcome glioblastoma resistance and recurrence and improve patient survival are necessary.

This Special Issue will assemble preclinical and clinical studies of novel therapeutic strategies for glioblastoma. In addition, reviews referring to glioblastoma research and therapy will be appreciated.

Deadline for manuscript  
submissions:  
**closed (31 May 2024)**



[mdpi.com/si/121970](https://mdpi.com/si/121970)

- glioblastoma
- novel therapeutic strategies
- preclinical models
- clinical studies
- resistance to therapy
- gene therapy
- stem cell therapy
- immunotherapy
- natural compounds

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma